HbA1c – cessation of dual reporting
Haemoglobin A1c (HbA1c) is glycosylated haemoglobin, ie haemoglobin that has glucose bound to it. The amount is directly related to an individual’s glucose levels over the previous two to three months, making it a better overall indicator of average glucose than a single snapshot glucose measurement.
To date, Synnovis has continued to report HbA1c using both the historical Diabetes Control and Complications Trial (DCCT) measurement as a percentage of total haemoglobin, and the newer standardised International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) method as a ratio of HbA1c to non-glucose bound haemoglobin, reported as mmol/mol.
Feedback from primary and community care colleagues has told us that dual reporting is not only time-consuming to process and file, but that it adds no benefit to patient care. As a result, we are in the process of moving to reporting only the IFCC-preferred units of mmol/mol.
We are also reviewing the clinical comments we provide for HbA1c results to streamline them across all south east London boroughs.
Please let us know about any other aspects of clinical guidance that you feel would be helpful, by either speaking to your GP clinical leads or to our Customer Services team.